Protagonist Therapeutics Stock Forecast, Price & News

Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions

Is Protagonist Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Protagonist Therapeutics stock.
View analyst ratings for Protagonist Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Protagonist Therapeutics?

Wall Street analysts have given Protagonist Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Protagonist Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Protagonist Therapeutics?

Protagonist Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 3,640,000 shares, an increase of 27.3% from the September 15th total of 2,860,000 shares. Based on an average trading volume of 1,720,000 shares, the days-to-cover ratio is currently 2.1 days. Currently, 8.7% of the company's shares are sold short.
View Protagonist Therapeutics' Short Interest.

When is Protagonist Therapeutics' next earnings date?

Protagonist Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Protagonist Therapeutics.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) released its earnings results on Wednesday, August, 4th. The company reported ($0.69) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.55) by $0.14. The company earned $2.27 million during the quarter, compared to the consensus estimate of $5.60 million. Protagonist Therapeutics had a negative net margin of 299.39% and a negative trailing twelve-month return on equity of 30.58%.
View Protagonist Therapeutics' earnings history.

How has Protagonist Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Protagonist Therapeutics' stock was trading at $7.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PTGX shares have increased by 320.7% and is now trading at $30.12.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for PTGX?

7 brokers have issued 12 month target prices for Protagonist Therapeutics' stock. Their forecasts range from $40.00 to $93.00. On average, they expect Protagonist Therapeutics' share price to reach $56.75 in the next year. This suggests a possible upside of 88.4% from the stock's current price.
View analysts' price targets for Protagonist Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Protagonist Therapeutics' key executives?

Protagonist Therapeutics' management team includes the following people:

• Dinesh V. Patel, President, Chief Executive Officer & Director
• Donald A. Kalkofen, Chief Financial Officer
• Mark L. Smythe, Vice President-Technology
• David Y. Liu, Chief Scientific Officer (LinkedIn Profile)
• Samuel R. Saks, Chief Medical Officer

Who are some of Protagonist Therapeutics' key competitors?

Some companies that are related to Protagonist Therapeutics include Allakos (ALLK), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Cerevel Therapeutics (CERE), I-Mab (IMAB), Alkermes (ALKS), TG Therapeutics (TGTX), Mawson Infrastructure Group (WIZP), Ionis Pharmaceuticals (IONS), Arvinas (ARVN), Schrödinger (SDGR), Arena Pharmaceuticals (ARNA), Karuna Therapeutics (KRTX), 23andMe (ME) and Reata Pharmaceuticals (RETA).
View all of PTGX's competitors.

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $30.12.

How much money does Protagonist Therapeutics make?

Protagonist Therapeutics has a market capitalization of $1.43 billion and generates $28.63 million in revenue each year. The company earns $-66.15 million in net income (profit) each year or ($1.92) on an earnings per share basis.

How many employees does Protagonist Therapeutics have?

Protagonist Therapeutics employs 79 workers across the globe.

What is Protagonist Therapeutics' official website?

The official website for Protagonist Therapeutics is www.protagonist-inc.com.

Where are Protagonist Therapeutics' headquarters?

Protagonist Therapeutics is headquartered at 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at (510) 474-0170 or via email at [email protected].